Literature DB >> 2323837

N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS.

P Dias1, P Kumar, H B Marsden, H R Gattamaneni, J Heighway, S Kumar.   

Abstract

DNA from 13 (6 alveolar and 7 embryonal) childhood rhabdomyosarcomas (RMS) was examined to determine the incidence and prognostic relevance of N- and c-myc genes. Southern analysis showed 5- to 20-fold amplification of N-myc gene in 4 of 6 alveolar but in none of 7 embryonal RMS (p less than 0.04; Fisher's exact test). The number of children who died with multiple- and single-copy N-myc gene was 4/4 and 5/9 respectively (p greater than 0.05; Chi-squared test). There was no statistically significant correlation between N-myc amplification and age, gender, site, stage or survival time. There was no amplification or gross rearrangement of c-myc in any of the 13 RMS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323837     DOI: 10.1002/ijc.2910450403

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma.

Authors:  A Pandita; M Zielenska; P Thorner; J Bayani; R Godbout; M Greenberg; J A Squire
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 2.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

3.  The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Authors:  Hemant K Bid; Doris A Phelps; Linlin Xaio; Denis C Guttridge; Jiayuh Lin; Cheryl London; Laurence H Baker; Xiaokui Mo; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2016-02-23       Impact factor: 6.261

4.  MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification.

Authors:  O B Chernova; M V Chernov; Y Ishizaka; M L Agarwal; G R Stark
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

Review 5.  Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours.

Authors:  J F Graadt van Roggen; J V Bovée; J Morreau; P C Hogendoorn
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

6.  SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.

Authors:  Xiaosong Hu; Ruochen Liu; Jianbing Hou; Wen Peng; Sicheng Wan; Minghao Xu; Yongsen Li; Guanghui Zhang; Xuan Zhai; Ping Liang; Hongjuan Cui
Journal:  Oncogene       Date:  2022-08-17       Impact factor: 8.756

7.  Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma.

Authors:  D N Shapiro; M B Valentine; S T Rowe; A E Sinclair; J E Sublett; W M Roberts; A T Look
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  The mTOR pathway negatively controls ATM by up-regulating miRNAs.

Authors:  Changxian Shen; Peter J Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

9.  Fusion of the Paired Box 3 (PAX3) and Myocardin (MYOCD) Genes in Pediatric Rhabdomyosarcoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Marius Lund-Iversen; Svetlana Tafjord; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

10.  Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma.

Authors:  Alan C Taylor; Katja Schuster; Pamela P McKenzie; Linda C Harris
Journal:  Mol Cancer       Date:  2006-11-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.